Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 210.8M
Operating Income 47.0M 22.30%
Net Income 65.6M 31.13%

Balance Sheet Metrics

Total Assets 526.3M
Total Liabilities 97.6M
Shareholders Equity 428.7M
Debt to Equity 0.23

Cash Flow Metrics

Operating Cash Flow -25.5M
Free Cash Flow -44.7M

Revenue & Profitability Trend

Entrada Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue210.8M129.0M000
Cost of Goods Sold-----
Gross Profit-----
Operating Expenses163.8M132.2M97.2M51.1M26.7M
Operating Income47.0M-3.2M-97.2M-51.1M-26.7M
Pre-tax Income66.5M12.1M-94.6M-51.2M-26.5M
Income Tax859.0K18.7M0--
Net Income65.6M-6.7M-94.6M-51.2M-26.5M
EPS (Diluted)--$0.20-$3.02-$8.16-$1.30

Income Statement Trend

Entrada Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets440.0M369.8M209.9M298.7M39.9M
Non-Current Assets86.3M99.4M42.2M7.1M3.6M
Total Assets526.3M469.2M252.1M305.8M43.5M
Liabilities
Current Liabilities39.5M158.8M22.0M6.7M3.4M
Non-Current Liabilities58.2M68.0M17.5M396.0K81.7M
Total Liabilities97.6M226.8M39.5M7.1M85.0M
Equity
Total Shareholders Equity428.7M242.4M212.6M298.7M-41.5M

Balance Sheet Composition

Entrada Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income65.6M-6.7M-94.6M-51.2M-26.5M
Operating Cash Flow-25.5M129.1M-81.7M-48.2M-25.9M
Investing Activities
Capital Expenditures-3.2M-5.6M-2.9M-4.6M-2.3M
Investing Cash Flow-27.8M-138.4M-148.6M-4.6M-2.3M
Financing Activities
Dividends Paid-----
Financing Cash Flow99.6M19.4M0306.5M49.8M
Free Cash Flow-44.7M134.2M-96.7M-55.4M-27.9M

Cash Flow Trend

Entrada Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 12.34
Forward P/E -2.27
Price to Book 0.60
Price to Sales 1.58
PEG Ratio -2.27

Profitability Ratios

Profit Margin 14.39%
Operating Margin -105.99%
Return on Equity 7.22%
Return on Assets 0.51%

Financial Health

Current Ratio 21.88
Debt to Equity 13.66
Beta -0.06

Per Share Data

EPS (TTM) $0.58
Book Value per Share $11.84
Revenue per Share $4.39

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
trda271.7M12.340.607.22%14.39%13.66
Vertex 124.2B32.827.53-5.64%-8.91%10.00
Regeneron 59.1B13.921.9715.96%31.94%9.20
Cg Oncology 2.0B-19.182.81-16.58%0.00%0.15
Belite Bio 1.9B-54.3712.07-33.43%0.00%0.00
Disc Medicine 1.9B4.992.93-23.34%0.00%4.64

Financial data is updated regularly. All figures are in the company's reporting currency.